Aclaris Therapeutics Inc (ACRS)
1.32
0.00 (0.00%)
USD |
NASDAQ |
May 07, 13:01
Aclaris Therapeutics Cash from Investing (Quarterly): 7.55M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.55M |
| September 30, 2023 | 32.53M |
| June 30, 2023 | -19.66M |
| March 31, 2023 | 25.80M |
| December 31, 2022 | 2.702M |
| September 30, 2022 | 1.217M |
| June 30, 2022 | -21.22M |
| March 31, 2022 | 29.93M |
| December 31, 2021 | -9.176M |
| September 30, 2021 | -37.67M |
| June 30, 2021 | -45.47M |
| March 31, 2021 | -75.31M |
| December 31, 2020 | -2.305M |
| September 30, 2020 | 5.237M |
| June 30, 2020 | -10.49M |
| March 31, 2020 | 13.94M |
| December 31, 2019 | 56.44M |
| September 30, 2019 | 21.67M |
| Date | Value |
|---|---|
| June 30, 2019 | 18.95M |
| March 31, 2019 | 8.616M |
| December 31, 2018 | -70.51M |
| September 30, 2018 | 10.39M |
| June 30, 2018 | 13.29M |
| March 31, 2018 | 56.19M |
| December 31, 2017 | -21.56M |
| September 30, 2017 | -39.86M |
| June 30, 2017 | -0.226M |
| March 31, 2017 | 5.956M |
| December 31, 2016 | -77.82M |
| September 30, 2016 | -4.127M |
| June 30, 2016 | 9.868M |
| March 31, 2016 | 10.17M |
| December 31, 2015 | -69.49M |
| September 30, 2015 | -13.12M |
| June 30, 2015 | 4.91M |
| March 31, 2015 | 0.745M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-75.31M
Minimum
Mar 2021
56.44M
Maximum
Dec 2019
-0.2807M
Average
2.702M
Median
Dec 2022
Cash from Investing (Quarterly) Benchmarks
| Aldeyra Therapeutics Inc | -30.38M |
| Akoya Biosciences Inc | -0.594M |
| CEL-SCI Corp | -0.0649M |
| AIM ImmunoTech Inc | -0.214M |
| IGC Pharma Inc | -0.061M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -6.761M |
| Cash from Financing (Quarterly) | 0.049M |
| Free Cash Flow | -79.63M |
| Free Cash Flow Per Share (Quarterly) | -0.1016 |
| Free Cash Flow to Equity (Quarterly) | -7.202M |
| Free Cash Flow Yield | -86.43% |